Peronne

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Researchers are evaluating the safety and performance of the SYMBOL range of medical devices used in total hip arthroplasty hip replacement surgery. This observational study aims to monitor outcomes over a period of 10 years in patients who receive these devices, assessing their durability and overall impact on hip joint health. The study is sponsored by Dedienne Sante S.A.S. and focuses on conditions such as degenerative hip joint disease, post-traumatic osteoarthritis, hip arthritis, femoral neck fractures, avascular necrosis of the femoral head, and failure of prosthetic joint implants. Participants undergo total hip arthroplasty involving at least one medical device from the SYMBOL range. The study includes patients receiving either primary or revision hip replacement surgery with these devices. There is no randomized assignment or placebo group, as this is an observational follow-up of patients treated with SYMBOL devices. The study spans up to 10 years post-operation, with specific evaluation timepoints at 6 months, 18 months, 5 years, and 10 years after surgery. During the study, participants will have regular assessments including radiographic evaluations to check for implant stability and bone changes, as well as clinical evaluations using the Harris Hip Score and pain intensity scales. Patient-reported measures such as quality of life EQ-5D-5L and satisfaction with the hip joint will also be collected. The main outcome measure is the survivorship of individual SYMBOL orthopaedic components 10 years after surgery. Safety will be monitored by recording any adverse device effects throughout the study period, with follow-up lasting an average of 10 years.